Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study

BACKGROUND: Detecting pre-clinical bladder cancer (BC) using urinary biomarkers may provide a valuable opportunity for screening and management. Telomerase reverse transcriptase (TERT) promoter mutations detectable in urine have emerged as promising BC biomarkers. METHODS: We performed a nested case...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:EBioMedicine
Egile Nagusiak: Hosen, Md Ismail, Sheikh, Mahdi, Zvereva, Maria, Scelo, Ghislaine, Forey, Nathalie, Durand, Geoffroy, Voegele, Catherine, Poustchi, Hossein, Khoshnia, Masoud, Roshandel, Gholamreza, Sotoudeh, Masoud, Nikmanesh, Arash, Etemadi, Arash, Avogbe, Patrice Hodonou, Chopard, Priscilia, Delhomme, Tiffany Myriam, Foll, Matthieu, Manel, Arnaud, Vian, Emmanuel, Weiderpass, Elisabete, Kamangar, Farin, Boffetta, Paolo, Pharaoh, Paul D., Dawsey, Sanford M., Abnet, Christian C., Brennan, Paul, McKay, James, Malekzadeh, Reza, Calvez-Kelm, Florence Le
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2020
Gaiak:
Research paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7118568/
https://ncbi.nlm.nih.gov/pubmed/32081602
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2020.102643
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak